A FAPI-based small-molecule drug conjugate alleviates rheumatoid arthritis by targeting pathogenic FAPα-expressing fibroblasts
{{output}}
The management of rheumatoid arthritis (RA) has advanced into the realm of targeted therapies; however, these therapies often lack tissue specificity and cause systemic adverse effects. Fibroblast-activating protein α (FAPα+) expressing fibroblast-like synov... ...
